Actively Recruiting
Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma
Led by University of Alabama at Birmingham · Updated on 2025-12-26
14
Participants Needed
1
Research Sites
258 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This pilot clinical study will investigate if Zirconium-89 (89Zr) panitumumab- Positron Emission Tomography/ Magnetic Resonance Imaging (PET/MRI) imaging can more accurately determine size and location of primary tumors compared to standard of care Fludeoxyglucose (18F-FDG) -PET/MRI in newly diagnosed patients with head and neck squamous cell carcinoma (HNSCC) who are undergoing surgical resection. This study is for imaging purposes only and is not a treatment study. The results of this study will not change the clinical treatment plan.
CONDITIONS
Official Title
Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Biopsy-confirmed diagnosis of squamous cell carcinoma of the head and neck
- Newly diagnosed patients with any T stage and any head and neck subsite who are scheduled for surgical resection
- Clinically and radiographically node negative (cN0) based on preoperative evaluation
- Planned standard of care surgery with curative intent for squamous cell carcinoma
- Age over 18 years
- Acceptable blood counts and organ function, including hemoglobin at least 9 gm/dL, white blood cell count at least 3000/mm3, platelet count at least 100,000/mm3, serum creatinine no greater than 1.5 times upper limit, ALT 7-56 units/liter, and AST 5-40 units/liter
You will not qualify if you...
- Received any investigational drug within 30 days before the first dose of 89Zr panitumumab
- History of heart attack, stroke, uncontrolled heart failure, significant liver disease, or unstable angina within 6 months prior to enrollment
- Previous surgery for head and neck squamous cell carcinoma
- History of infusion reactions to monoclonal antibody therapies
- Pregnant or breastfeeding women
- Low magnesium (less than 1.7 mg/dL) or potassium (less than 3.6 mmol/L) levels
- Currently taking Class I-A or Class III antiarrhythmic medications
- History or evidence of interstitial pneumonitis or pulmonary fibrosis
- Severe kidney disease or anuria
- Known allergy to panitumumab or its components
- Weight over 350 pounds due to scanner size limitations
- Contraindications to MRI such as non-removable metal implants or certain tattoos
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UAB
Birmingham, Alabama, United States, 35249
Actively Recruiting
Research Team
S
Sebastian Eady, BS
CONTACT
C
Chase Bower
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here